Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 1
1992 1
1993 3
1994 1
1995 3
1996 1
1997 4
1998 6
1999 29
2000 19
2001 23
2002 54
2003 36
2004 79
2005 97
2006 107
2007 122
2008 126
2009 170
2010 233
2011 230
2012 276
2013 299
2014 303
2015 299
2016 304
2017 294
2018 302
2019 293
2020 341
2021 341
2022 346
2023 265
2024 259
2025 314
2026 158

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,099 results

Results by year

Filters applied: . Clear all
Page 1
Pemetrexed disodium.
Gibbs D, Jackman A. Gibbs D, et al. Nat Rev Drug Discov. 2005 May;Suppl:S16-7. doi: 10.1038/nrd1731. Nat Rev Drug Discov. 2005. PMID: 15962527 Review.
In February 2004, pemetrexed disodium (Alimta; Eli Lilly), an anticancer drug that targets folate-dependent reactions that are essential for cell proliferation, became the first drug to be approved by the US FDA for the treatment of the rare cancer malignant pleural …
In February 2004, pemetrexed disodium (Alimta; Eli Lilly), an anticancer drug that targets folate-dependent reactions that are …
Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity.
de Rouw N, Piet B, Derijks HJ, van den Heuvel MM, Ter Heine R. de Rouw N, et al. Drug Saf. 2021 Dec;44(12):1271-1281. doi: 10.1007/s40264-021-01135-2. Epub 2021 Nov 6. Drug Saf. 2021. PMID: 34741752 Review.
Pemetrexed is a cytostatic antifolate drug and a cornerstone in the treatment of lung cancer. ...Moreover, high-dose folinic acid can resolve severe pemetrexed-induced toxicity. There are several experimental options to prevent or manage pemetrexed-related to …
Pemetrexed is a cytostatic antifolate drug and a cornerstone in the treatment of lung cancer. ...Moreover, high-dose folinic acid can …
Pemetrexed disodium (Eli Lilly).
Norman P. Norman P. Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22. Curr Opin Investig Drugs. 2001. PMID: 11763166 Review.
Pemetrexed, a thymidylate synthase (TS) and transferase inhibitor, is in phase III trials with Eli Lilly as a potential treatment for several common solid tumors, including non-small cell lung cancer (NSCLC) and mesothelioma [321789], [410731]. Studies on pemetrexed …
Pemetrexed, a thymidylate synthase (TS) and transferase inhibitor, is in phase III trials with Eli Lilly as a potential treatment for …
Pemetrexed disodium, a novel antifolate with multiple targets.
Curtin NJ, Hughes AN. Curtin NJ, et al. Lancet Oncol. 2001 May;2(5):298-306. doi: 10.1016/s1470-2045(00)00325-9. Lancet Oncol. 2001. PMID: 11905785 Review.
Pemetrexed disodium is a potent new antifolate which inhibits many folate-dependent reactions that are essential for cell proliferation. ...Cells that are resistant to antifolates are generally less resistant to pemetrexed, irrespective of the mechanism of re …
Pemetrexed disodium is a potent new antifolate which inhibits many folate-dependent reactions that are essential for cell prol …
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Vogelzang NJ, et al. J Clin Oncol. 2003 Jul 15;21(14):2636-44. doi: 10.1200/JCO.2003.11.136. J Clin Oncol. 2003. PMID: 12860938 Clinical Trial.
The hazard ratio for death of patients in the pemetrexed/cisplatin arm versus those in the control arm was 0.77. Median time to progression was significantly longer in the pemetrexed/cisplatin arm: 5.7 months versus 3.9 months (P =.001). Response rates were 41.3% in …
The hazard ratio for death of patients in the pemetrexed/cisplatin arm versus those in the control arm was 0.77. Median time to progr …
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Kurata T, Yang J, Pietanza MC, Souza F, Garassino MC. Rodríguez-Abreu D, et al. Ann Oncol. 2021 Jul;32(7):881-895. doi: 10.1016/j.annonc.2021.04.008. Epub 2021 Apr 22. Ann Oncol. 2021. PMID: 33894335 Free article. Clinical Trial.
BACKGROUND: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated m …
BACKGROUND: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemet …
Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
Hanauske AR, Chen V, Paoletti P, Niyikiza C. Hanauske AR, et al. Oncologist. 2001;6(4):363-73. doi: 10.1634/theoncologist.6-4-363. Oncologist. 2001. PMID: 11524555 Free article. Review.
Pemetrexed disodium (ALIMTA), "pemetrexed") is a novel, multi-targeted antifolate that has demonstrated promising clinical activity in a wide variety of solid tumors, including non-small cell lung, breast, mesothelioma, colorectal, pancreatic, gastric, bladde …
Pemetrexed disodium (ALIMTA), "pemetrexed") is a novel, multi-targeted antifolate that has demonstrated promising clini …
Pemetrexed disodium in ovarian cancer treatment.
Morotti M, Valenzano Menada M, Venturini PL, Mammoliti S, Ferrero S. Morotti M, et al. Expert Opin Investig Drugs. 2012 Apr;21(4):437-49. doi: 10.1517/13543784.2012.661714. Epub 2012 Feb 13. Expert Opin Investig Drugs. 2012. PMID: 22324304 Review.
Many drugs are available but recently a renewed interest is addressed on antimetabolite drugs. Pemetrexed (PEM) is a multitargeted antifolate cytotoxic agent mainly used in lung cancer. ...
Many drugs are available but recently a renewed interest is addressed on antimetabolite drugs. Pemetrexed (PEM) is a multitargeted an …
Pemetrexed disodium.
Muhsin M, Gricks C, Kirkpatrick P. Muhsin M, et al. Nat Rev Drug Discov. 2004 Oct;3(10):825-6. doi: 10.1038/nrd1528. Nat Rev Drug Discov. 2004. PMID: 15497247 No abstract available.
Safety of dose-reduced pemetrexed in patients with renal insufficiency.
Hill J, Vargo C, Smith M, Streeter J, Carbone DP. Hill J, et al. J Oncol Pharm Pract. 2019 Jul;25(5):1125-1129. doi: 10.1177/1078155218780507. Epub 2018 Jun 5. J Oncol Pharm Pract. 2019. PMID: 29871545

PURPOSE: Pemetrexed has been shown to be effective in the treatment of advanced and metastatic nonsquamous nonsmall cell lung cancer. ...The fourth patient had a CrCl < 30 ml/min. No patients receiving single-agent pemetrexed with a CrCl > 30 ml/min experience

…
PURPOSE: Pemetrexed has been shown to be effective in the treatment of advanced and metastatic nonsquamous nonsmall cell lung cancer. …
5,099 results